Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT02863419

Public ClinicalTrials.gov record NCT02863419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02863419
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
711 participants

Conditions and interventions

Interventions

  • semaglutide Drug
  • liraglutide Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 9, 2016
Primary completion
Aug 18, 2017
Completion
Mar 29, 2018
Last update posted
Jul 19, 2022

2016 – 2018

United States locations

U.S. sites
40
U.S. states
19
U.S. cities
37
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35222
Novo Nordisk Investigational Site Los Alamitos California 90720
Novo Nordisk Investigational Site San Diego California 92111
Novo Nordisk Investigational Site Denver Colorado 80246
Novo Nordisk Investigational Site Hallandale Florida 33009
Novo Nordisk Investigational Site Jacksonville Florida 32256
Novo Nordisk Investigational Site Miami Florida 33155
Novo Nordisk Investigational Site Ocala Florida 34470
Novo Nordisk Investigational Site Orlando Florida 32801
Novo Nordisk Investigational Site Orlando Florida 32804
Novo Nordisk Investigational Site Ormond Beach Florida 32174-6302
Novo Nordisk Investigational Site St. Petersburg Florida 33713
Novo Nordisk Investigational Site West Palm Beach Florida 33401
Novo Nordisk Investigational Site Peoria Illinois 61603
Novo Nordisk Investigational Site Topeka Kansas 66606
Novo Nordisk Investigational Site Slidell Louisiana 70461-4231
Novo Nordisk Investigational Site Butte Montana 59701
Novo Nordisk Investigational Site Lebanon New Hampshire 03756
Novo Nordisk Investigational Site Teaneck New Jersey 07666
Novo Nordisk Investigational Site Albany New York 12203
Novo Nordisk Investigational Site Mineola New York 11501
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Morganton North Carolina 28655
Novo Nordisk Investigational Site Wilmington North Carolina 28401
Novo Nordisk Investigational Site Dublin Ohio 43016
Novo Nordisk Investigational Site Maumee Ohio 43537
Novo Nordisk Investigational Site Norman Oklahoma 73069
Novo Nordisk Investigational Site McMurray Pennsylvania 15317
Novo Nordisk Investigational Site Summerville South Carolina 29485
Novo Nordisk Investigational Site Bristol Tennessee 37620-7352
Novo Nordisk Investigational Site Arlington Texas 76012-4637
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75390-9302
Novo Nordisk Investigational Site Houston Texas 77004-7000
Novo Nordisk Investigational Site North Richland Hills Texas 76180
Novo Nordisk Investigational Site San Antonio Texas 78229
Novo Nordisk Investigational Site San Antonio Texas 78249
Novo Nordisk Investigational Site Newport News Virginia 23606
Novo Nordisk Investigational Site Richmond Virginia 23219
Novo Nordisk Investigational Site Virginia Beach Virginia 23454

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02863419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 19, 2022 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02863419 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →